CCP Animal Models for Drug Efficacy or Research Studies

• Covid-19 models – AAV humanized and constitutive or inducible huACE-2 mutant mice
• Lung fibrosis and asthma models – lung function measurements, bronchoalveolar lavage and histopathological analysis
• CDX/PDX models of cancer – syngenic and allogenic models of cancer diseases, standardized for efficacy studies, including ortho-topic application (blood, ovarial fat pad, breast, pancreas, kidney, other), including cancer cells modification to enable imaging (e.g. luciferase system)
• DSS induced colitis/ AOM-DSS model of colitis induced cancerogenesis (Bl6, Apcmin )
• Obesity & Diabetes – high fat/carbohydrate diet, Streptozotocin induced model, ob/ob mouse model – with comprehensive testing pipeline
• Cardiovascular diseases – ECG & Echo & blood pressure (mutant mice including embryos, newborns, various heart challenges, veins and arteries, diet induced atherosclerosis)
• Rare disease models – Netherton syndrome, Prader-Willi syndrome, Angelmann syndrome, Osteogenesis imperfecta Aga2 model, DBA (anemia), customized – specific human gene variant
• Immune system diseases
• Skeleton diseases – CIA model of rheumatoid arthritis in DBA/1 mice, osteoporosis, developmental pathologies – craniofacial malformations, teeth development
• New GM mouse/rat disease models development – more rare or other disease GM models under development or on demand
• Other induced disease models on demand – chemically induced inflammation, infection models, injury models